menu search

Shareholder alert: the m&a class action firm continues its investigation of the merger – angn, focs, unvr, csii

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the �...

April 12, 2023, 9:20 pm

Shareholder alert: the m&a class action firm continues investigating the merger – angn, cnce, vlon

NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the �...

January 21, 2023, 1:00 am

angion (angn) down on merger agreement with private biotech

angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined ...

January 18, 2023, 2:18 pm

angion receives nasdaq notice regarding minimum bid price requirements

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) — angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceu...

December 22, 2022, 2:50 am

angion biomedica pulls the plug on another kidney disease trial - read why

angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral...

June 30, 2022, 6:11 am

angion (angn) kidney drug misses third study goal in 2021

angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fa...

December 13, 2021, 1:50 pm

angion (angn) kidney drug misses third study goal in 2021

angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fa...

December 13, 2021, 1:50 pm

angion (angn) kidney drug misses third study goal in 2021

angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fa...

December 13, 2021, 1:50 pm


Search within

Pages Search Results: